about
Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.Advances in glucocorticoid-induced osteoporosisDeficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosusSystemic lupus erythematosus and fractures.Osteoporosis and fractures in systemic lupus erythematosus.Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge.Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study.Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom.Body mass index measurements have limited value for the assessment of body composition in rheumatoid arthritis: comment on the article by Wolfe and Michaud.The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus.Optimizing fracture prevention: the fracture liaison service, an observational study.Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus.Depression in systemic lupus erythematosus, dependent on or independent of severity of disease.Unexpected severe incident vertebral fractures in patients with systemic lupus erythematosus: comment on the article by Zhu et al.Long-term clinical outcomes in a cohort of adults with childhood-onset Systemic Lupus ErythematosusFerritin and serum transferrin receptor predict iron deficiency in anemic patients with rheumatoid arthritisFusobacterium nucleatum septicemia and portal vein thrombosisDevelopment of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et alGlucocorticoid-induced osteoporosisPrevention of glucocorticoid-induced osteoporosisStable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritisRelevance of the new pre-cachexia and cachexia definitions for patients with rheumatoid arthritisThe association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter studyEstimation of dietary calcium intakePerformance of vertebral fracture assessment in addition to dual energy X-ray absorptiometry in patients with rheumatoid arthritisMaking the invisible visible: bioelectrical impedance analysis demonstrates unfavourable body composition in rheumatoid arthritis patients in clinical practiceCurrent Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
P50
Q33482516-F16A1414-45A0-4CF4-92F7-271BA6B72D77Q33966587-C80D8981-60BF-46F3-AF99-3E9EB2AA78B7Q34545102-954491E8-091F-4A68-831F-4AE77E1F5AD4Q34975913-69281DDA-8D9B-40AF-86FF-9E07FDBC6D79Q35630117-9B0871E0-F7A2-4200-ACE2-6FD5251421BEQ36246074-878AC83C-1FC0-407D-B541-CA224CC6DB75Q37972874-729129CA-6B6A-4FE0-ACDD-BDC27CA07755Q38163093-238CAEF6-3D6F-4F4F-B517-27125C645FE1Q42771406-59D31044-A3B2-4486-A719-D15D688F21F7Q43180633-B1A5BE00-27AD-4EF3-9C06-2926EA5A7552Q44250901-584176AE-635F-4385-8E88-A713CCAADA80Q45332774-3C4854C1-F6C0-4A45-8916-3CFCC8646164Q46481741-A253F30D-91ED-4F7B-B893-B5C4861FDD36Q46573574-9B35E33F-4B30-49DA-A3E6-F7617FD3484FQ46629681-194CCF92-5713-4D16-B8BA-A23746EDEAD5Q47952057-07242CD2-9635-453F-9F38-650E900B489DQ48412705-EA29573A-57BB-45AC-9D82-9B550C93ECA8Q53725504-A5B154DA-75AA-42D6-B4C6-0060959F7FC8Q57167326-B4020863-8ECD-465C-9569-8E25A19E5986Q73792199-3D544CB8-55B8-4D7E-B4AB-103D13184635Q78139772-33796950-35ED-4250-8EAA-CDA2601A7806Q81629364-261B077B-6FB2-4015-864F-B39CE5047AD1Q82140545-2FB6759B-92CB-420E-B132-1D1ABCD8EAECQ83620815-E152CB96-FFB4-483E-A306-71AD747D7DB3Q84171677-FAD5C4EC-C5C2-4968-B4CF-2C38FE5802B3Q84371074-8709FD7D-E346-41EC-B3E8-661D7ED83F68Q84438431-B704CE43-4526-49AD-A1B3-BCF441223646Q85217066-D9E0061C-B430-4536-87E5-68503AEA09E9Q87115109-512ED750-8A81-4476-834B-9582B2E8E794Q87813748-A86320CD-DEDA-4C05-81EE-A69AAB9F6D79Q92764151-DCC88870-12A5-40AC-82A2-798C88DC96CC
P50
description
researcher
@en
name
Bultink IE
@nl
Irene E. Bultink
@en
type
label
Bultink IE
@nl
Irene E. Bultink
@en
altLabel
Bultink IE
@en
prefLabel
Bultink IE
@nl
Irene E. Bultink
@en
P106
P31
P496
0000-0002-5441-3420